HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Hiroaki Nomori Takashi Ohtsuka Tsuguo Naruke Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nomori, H. Articles by Uno, K. Search for Related Content PubMed PubMed Citation Articles by Nomori, H. Articles by Uno, K. Related Collections Lung - cancer

J Thorac Cardiovasc Surg 2004;127:1087-1092
© 2004 The American Association for Thoracic Surgery

General thoracic surgery

The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer

^a Department of Thoracic Surgery, Saiseikai Central Hospital, Tokyo, Japan
^b Nishidai Clinic, Tokyo, Japan

Received for publication June 13, 2003; revisions received July 14, 2003; revisions received July 23, 2003; accepted for publication August 11, 2003.

^* Address for reprints: Hiroaki Nomori, MD, Department of Thoracic Surgery, Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo 108-0073, Japan
hnomori{at}qk9.so-net.ne.jp

BACKGROUND: We examined the sizes of lymph nodes and metastatic foci within the lymph nodes that affect false-positive and false-negative lymph node staging by positron emission tomography in lung cancer.

METHODS: Preoperative positron emission tomography and computed tomography scans were performed for 564 lymph node stations in 80 patients with peripheral-type lung cancer. The sizes of both the lymph nodes and the metastatic foci within the lymph nodes were measured, and these measurements were compared with those obtained with positron emission tomography scanning. To establish general sizes of metastatic foci within the lymph nodes, 277 metastatic lymph nodes in operative specimens previously resected from another 111 patients with lung cancer were examined as a control.

RESULTS: The sensitivity was significantly higher for positron emission tomography than for computed tomographic scanning (P = .026). The sizes of metastatic foci within lymph nodes that showed false-negative (n = 8) and true-positive (n = 28) with positron emission tomography ranged from 0.5 to 9 mm (3 ± 1 mm) and from 4 to 18 mm (10 ± 3 mm), respectively (P < .001). None of the metastatic foci smaller than 4 mm could be detected with positron emission tomography scanning. The review of the 277 previously resected metastatic lymph nodes showed that 89 (32%) had metastatic foci smaller than 4 mm. The sizes of true-positive (n = 28) and false-positive (n = 10) lymph nodes ranged from 6 to 15 mm (10 ± 2 mm) and from 9 to 16 mm (12 ± 2 mm), respectively (P < .01). None of the false-positive lymph nodes was smaller than 9 mm.

CONCLUSIONS: Although positron emission tomography was superior to computed tomography scanning in lymph node staging in lung cancer, positron emission tomography was unable to distinguish metastatic foci smaller than 4 mm, which were not unusual sizes for lymph node metastases in lung cancer. Positive lymph nodes with positron emission tomography smaller than 9 mm are likely to be true-positive rather than false-positive.

This article has been cited by other articles:

				H. Nomori, T. Mori, K. Ikeda, K. Kawanaka, S. Shiraishi, K. Katahira, and Y. Yamashita Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 816 - 822. [Abstract] [Full Text] [PDF]

				B. D. Kozower, B. F. Meyers, C. E. Reed, D. R. Jones, P. A. Decker, and J. B. Putnam Jr Does Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer? Ann. Thorac. Surg., April 1, 2008; 85(4): 1166 - 1170. [Abstract] [Full Text] [PDF]

				Y. C. Ung, D. E. Maziak, J. A. Vanderveen, C. A. Smith, K. Gulenchyn, C. Lacchetti, W. K. Evans, and Lung Cancer Disease Site Group of Cancer Care Onta 18Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer: A Systematic Review J Natl Cancer Inst, December 5, 2007; 99(23): 1753 - 1767. [Abstract] [Full Text] [PDF]

				G. A. Silvestri, M. K. Gould, M. L. Margolis, L. T. Tanoue, D. McCrory, E. Toloza, and F. Detterbeck Noninvasive Staging of Non-small Cell Lung Cancer: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 178S - 201S. [Abstract] [Full Text] [PDF]

				A. Mujoomdar, J. H. M. Austin, R. Malhotra, C. A. Powell, G. D. N. Pearson, M. C. Shiau, and H. Raftopoulos Clinical Predictors of Metastatic Disease to the Brain from Non-Small Cell Lung Carcinoma: Primary Tumor Size, Cell Type, and Lymph Node Metastases Radiology, March 1, 2007; 242(3): 882 - 888. [Abstract] [Full Text] [PDF]

				G. Massard, E. A. Kochetkova, V. A. Porhanov, and M. Riquet Reply to Belcher and Goldstraw Eur. J. Cardiothorac. Surg., January 1, 2007; 31(1): 143 - 144. [Full Text] [PDF]

				A. Ebihara, H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Uno, I. Kuwahira, and K. Eguchi Characteristics of Advantages of Positron Emission Tomography over Computed Tomography for N-staging in Lung Cancer Patients Jpn. J. Clin. Oncol., November 1, 2006; 36(11): 694 - 698. [Abstract] [Full Text] [PDF]

				G. Massard, X. Ducrocq, E. A. Kochetkova, V. A. Porhanov, and M. Riquet Sampling or node dissection for intraoperative staging of lung cancer: a multicentric cross-sectional study. Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 164 - 167. [Abstract] [Full Text] [PDF]

				K.-i. Watanabe, H. Nomori, T. Ohtsuka, T. Naruke, A. Ebihara, H. Orikasa, K. Yamazaki, K. Uno, T. Kobayashi, and T. Goya [F-18]Fluorodeoxyglucose Positron Emission Tomography Can Predict Pathological Tumor Stage and Proliferative Activity Determined by Ki-67 in Clinical Stage IA Lung Adenocarcinomas Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 403 - 409. [Abstract] [Full Text] [PDF]

				T. Bunyaviroch and R. E. Coleman PET Evaluation of Lung Cancer J. Nucl. Med., March 1, 2006; 47(3): 451 - 469. [Full Text] [PDF]

				J. L. Port, R. S. Andrade, M. A. Levin, R. J. Korst, P. C. Lee, D. E. Becker, and N. K. Altorki Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1611 - 1615. [Abstract] [Full Text] [PDF]

				T. Ohtsuka, H. Nomori, K. Watanabe, T. Naruke, H. Orikasa, K. Yamazaki, K. Suemasu, and K. Uno False-positive Findings on [18F]FDG-PET Caused by Non-neoplastic Cellular Elements After Neoadjuvant Chemoradiotherapy for Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 271 - 273. [Abstract] [Full Text] [PDF]

				H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Suemasu, and K. Uno Visual and Semiquantitative Analyses for F-18 Fluorodeoxyglucose PET Scanning in Pulmonary Nodules 1 cm to 3 cm in Size Ann. Thorac. Surg., March 1, 2005; 79(3): 984 - 988. [Abstract] [Full Text] [PDF]